What Is Inappropriate Sinus Tachycardia?

Inappropriate sinus tachycardia (IST) is a condition in which the heart’s natural pacemaker fires too fast without an obvious reason, pushing the resting heart rate above 100 beats per minute and producing symptoms like palpitations, dizziness, and shortness of breath. It overwhelmingly affects young women, is often confused with anxiety or depression, and remains one of the more frustrating diagnoses in cardiology because the heart itself is structurally normal. The underlying wiring is subtly off, and pinpointing exactly why has kept researchers busy for decades.

Who Gets It and How Common Is It

IST is not rare, but it is probably underdiagnosed. In a cohort study that identified 305 patients over several years, more than 92% were female, and the average age was about 33.¹ That demographic pattern shows up consistently across the literature: IST occurs predominantly in adolescents and young adults, with a strong female predominance.² The reasons for the sex skew are still unclear, though hormonal influences and differences in autonomic nervous system tone are frequently discussed possibilities. Healthcare workers, particularly nurses on long shifts, show up in case series with striking regularity, though whether that reflects a genuine occupational risk or just better access to heart-rate monitoring is an open question.

What Goes Wrong in the Body

The pathophysiology of IST is considered multifactorial, and autonomic dysfunction sits at the center of it.³ In plain terms, the heart has a built-in accelerator (the sympathetic nervous system) and a built-in brake (the parasympathetic, or vagal, system). People with IST seem to have the accelerator stuck partially down and the brake partially disconnected.

A landmark study from the early 1990s found that IST patients had an abnormally heightened sensitivity to adrenaline-like chemicals, roughly four times more sensitive than healthy controls. The same patients showed an unusually high intrinsic heart rate, meaning the sinus node itself was firing faster than normal even when stripped of all outside nervous-system input. Their vagal brake was also weaker.⁴ Later work confirmed three potential causal mechanisms: sympathetic receptor hypersensitivity, blunted parasympathetic tone, and enhanced intrinsic automaticity within the sinus node itself.⁵ Different patients may lean more heavily on one mechanism than the others, which partly explains why treatments that work well for one person can fail for the next.

An Autoimmune Clue

One of the more intriguing findings is that roughly half of IST patients carry antibodies that directly stimulate the heart’s adrenaline receptors. A study measuring the antibody activity of blood taken from IST patients found that about 52% had anti-beta-adrenergic receptor antibodies, and the antibody-containing fraction produced a clear, long-lasting increase in cellular signaling associated with a faster heart rate. No antibodies against the opposing cholinergic receptors were found.⁶ This raises the possibility that IST is, at least in some people, partly autoimmune: the immune system produces molecules that mimic adrenaline, keeping the heart rate artificially elevated. The finding has not yet translated into antibody-targeted treatments, but it has shifted how researchers think about the condition’s origins.

How IST Differs from POTS

Postural orthostatic tachycardia syndrome (POTS) is the condition most commonly confused with IST, and both share a demographic profile of young women with racing hearts. The key distinction is positional: in POTS, the heart rate spikes specifically when you stand up, typically rising by 30 beats per minute or more within ten minutes. In IST, the heart rate is elevated around the clock, whether you are sitting, lying down, or standing. A tilt-table test or a simple bedside stand test usually separates the two, though some patients meet criteria for both.

Physiologically, the two conditions look different under careful measurement. IST patients show a much larger sympathetic contribution to resting heart rate compared with POTS patients, roughly 31 beats per minute of sympathetic drive in IST versus about 12 in POTS. Parasympathetic tone trends lower in IST as well.⁷ Interestingly, when the sinus node’s intrinsic firing rate was measured after blocking both branches of the autonomic nervous system, there was no significant difference between IST patients, POTS patients, and healthy controls, suggesting the problem in IST lies less in the node hardware and more in the signals it receives.

There is also a point where elevated heart rate starts to become counterproductive. Research on how different tachycardia conditions affect the heart’s pumping efficiency found that the transition to reduced cardiac output occurred at a heart rate of about 115 beats per minute in IST patients, similar to the thresholds seen in POTS and vasovagal syncope.⁸ Above that threshold, the heart beats so fast it does not fill properly between beats, and output actually drops. That partly explains why people with IST feel worse with exertion rather than simply feeling their heart beating harder.

The Post-COVID Surge

IST entered wider public awareness after the COVID-19 pandemic because it turned up frequently in long-COVID clinics. In a prospective study of 200 patients seen at a post-COVID unit in 2020, one in five met diagnostic criteria for IST. These patients were predominantly young (average age 40), overwhelmingly female (85%), and most had experienced only mild COVID-19 illness. No structural heart disease, ongoing inflammation, or heart-muscle injury could explain their elevated heart rates.⁹

What the investigators did find was a clear drop in markers of parasympathetic tone: the vagal brake, once again, was impaired. When comparing post-COVID IST patients to fully recovered COVID survivors and to people who had never been infected, the parasympathetic markers showed a stepwise decline. This pattern mirrors the autonomic imbalance seen in pre-pandemic IST, suggesting that SARS-CoV-2 can trigger the same type of nerve dysfunction that has always been at the root of IST. Early autonomic-clinic experience confirmed that IST was among several dysautonomic conditions appearing after COVID-19 infection.¹⁰

Exercise capacity in these patients was strikingly low. The six-minute walk distance averaged about 392 meters, only 60% of what would be expected for their age and sex. Self-reported quality of life scored just 39 out of 100, with mobility and ability to carry out daily activities hit hardest.¹¹ Those numbers paint a picture of a condition that, while not immediately dangerous, can be profoundly disabling.

Getting Diagnosed (and Why It Takes So Long)

IST is a diagnosis of exclusion. Before it can be pinned down, every other possible cause of a fast heart rate has to be ruled out: thyroid disease, anemia, dehydration, medication side effects, pulmonary embolism, fever, pain, panic disorder, substance use including caffeine and alcohol, and withdrawal from beta-blockers.¹² A typical workup includes an ECG, blood tests for thyroid function and hemoglobin, sometimes a toxicology screen, and usually a 24-hour Holter monitor to confirm that the elevated rate persists around the clock. Echocardiography checks for structural heart problems, and exercise testing can reveal whether the heart rate response to exertion is disproportionate.

The challenge is that many patients first present to primary care or emergency rooms, where tachycardia in a young person with a normal-looking ECG and no fever can easily be attributed to anxiety. One striking case report described a young man with IST who was diagnosed with depression and treated with antidepressants for an extended period before a cardiologist eventually identified the true rhythm disorder. Once he underwent catheter ablation, his symptoms resolved.¹³ That case underscores a pattern familiar to many IST patients: months or years of being told the problem is psychological before someone orders the right test. The lesson for clinicians is that an elevated resting heart rate paired with palpitations and fatigue, especially if the heart rate rises disproportionately with minimal exertion, warrants a cardiology referral rather than an anxiety diagnosis alone.

Drug Treatment

For many years, beta-blockers were the default drug for IST, and they help some people. But they also lower blood pressure, cause fatigue, and do not address the sinus node itself. The drug that has changed the treatment landscape is ivabradine, which works by directly slowing the pacemaker current in the sinus node without affecting blood pressure or heart muscle contractility.

In a randomized, placebo-controlled, double-blind crossover trial, ivabradine eliminated more than 70% of symptoms, and nearly half of participants reported complete symptom resolution. Resting heart rate dropped from about 88 to 76 beats per minute, standing heart rate fell from roughly 108 to 92, and 24-hour average heart rate declined by about 11 beats per minute. Exercise performance improved as well.¹⁴ Based on results like these, ivabradine has emerged as the preferred pharmacological treatment for IST and has been shown to be more effective than beta-blockers.¹⁵

Ivabradine is not a cure. The heart rate tends to creep back up if the drug is stopped, and some patients still have residual symptoms even at optimal doses. Its most common side effect is visual disturbances, usually brief bright flashes in the peripheral vision, caused by the drug acting on a similar channel in the retina. It is also not approved for IST in every country; prescribing is sometimes off-label, which can create insurance hurdles. Still, for many IST patients, ivabradine is the first medication that meaningfully improves daily life without making them feel exhausted from low blood pressure.

Catheter Ablation and Newer Hybrid Approaches

When drugs fail, ablation enters the conversation. The idea is to use heat energy delivered through a catheter to modify the sinus node, essentially dialing down its firing rate. A systematic review of the published ablation literature found that about 86% of patients had successful outcomes initially, but symptomatic recurrence hit roughly 20%, and nearly a third still needed antiarrhythmic drugs afterward.¹⁶ An earlier single-center study put the longer-term success more modestly: after additional procedures in some cases, symptoms were ultimately eliminated in about two-thirds of patients.¹⁷

The problem with conventional sinus node ablation is that you are deliberately damaging the heart’s only natural pacemaker. Burn too little and the tachycardia recurs. Burn too much and the patient may need a permanent pacemaker, which trades one problem for another. In one study using three-dimensional mapping to guide ablation, the mean heart rate dropped to a normal 72 beats per minute, no patient needed a pacemaker over about three years of follow-up, and the recurrence rate was about 21%, with successful re-ablation in those cases.¹⁸

A newer approach tries to sidestep the pacemaker risk entirely. Hybrid thoracoscopic ablation combines a small keyhole surgical procedure on the outside of the heart with simultaneous catheter mapping on the inside. Early multicenter results were encouraging: all patients in the hybrid group had their normal sinus rhythm and rate restored, compared with 84% in the conventional catheter-only group. The hybrid group also needed far fewer redo procedures (8% versus 100% in the catheter-only group) and had a dramatically lower rate of permanent pacemaker implantation, only 4% versus 50%.¹⁹ A separate multicenter series reported complete symptom resolution and preserved normal sinus node function in all hybrid-ablation patients.²⁰ These are still small numbers and early follow-up, but the concept of ablating around the sinus node rather than through it represents a genuine shift in thinking about procedural treatment.

Long-Term Outlook

One of the more reassuring aspects of IST is that, despite how miserable it can make daily life, the long-term cardiac prognosis appears benign. There is no clear evidence that IST leads to heart failure, dangerous arrhythmias, or premature death.²¹ That finding is both good news and a source of frustration: because the condition is not considered dangerous, it can be dismissed by clinicians, and patients sometimes struggle to get the level of attention their symptoms warrant.

Quality of life, however, is a different story. The post-COVID data showing an average self-reported health score of 39 out of 100 puts IST patients in the same quality-of-life range as people with chronic heart failure. Fatigue, exercise intolerance, and the constant awareness of a pounding heart can interfere with work, social life, and mental health. Some patients do improve spontaneously over months or years, particularly those whose IST was triggered by a viral illness. Others have stable symptoms that require ongoing medication. Physical conditioning, specifically graded aerobic exercise programs, is frequently recommended alongside drug therapy, though it can be difficult to start when even minimal exertion triggers symptoms.

IST During Pregnancy

Pregnancy presents a particular challenge because the normal physiology of pregnancy already raises heart rate and cardiac output. In a person with IST, the additive effect can push symptoms to new extremes. The usual first-line drug for IST, ivabradine, has limited safety data in pregnancy and is generally avoided. Beta-blockers are considered safer for the fetus but, as noted, tend to be less effective for IST than ivabradine. Management during pregnancy typically involves a careful balance of the lowest effective medication dose, increased monitoring, and close collaboration between cardiology and obstetrics. The good news is that many women with IST tolerate pregnancy successfully, but planning ahead with your care team matters.

The Misdiagnosis Problem

Perhaps the most practical thing to understand about IST is how often it is missed. The symptoms, palpitations, fatigue, exercise intolerance, lightheadedness, and a general sense that something is wrong, overlap heavily with anxiety disorders, panic disorder, depression, and chronic fatigue syndrome. A normal ECG morphology (the heartbeat looks like a normal sinus beat, just faster than it should be) can lull clinicians into assuming the tachycardia is a stress response rather than a primary rhythm disorder.

If you suspect you might have IST, the most useful piece of evidence you can bring to a doctor is data. Wearable heart rate monitors, even consumer smartwatches, can reveal a pattern that is hard to dismiss: a resting heart rate consistently above 90 to 100 while sitting calmly, spikes well above 120 with minimal activity like walking to the kitchen, and a 24-hour average that stays elevated even during sleep. That pattern, combined with normal thyroid levels and no anemia, is a strong signal to push for a cardiology referral. A Holter monitor or multi-day ambulatory ECG recording remains the gold standard for confirming the diagnosis, but walking in with weeks of heart-rate data from a wearable can be the difference between being heard and being handed a prescription for an anti-anxiety medication.